A composition containing bird's nest acid, phospholipids and polyunsaturated fatty acids and preparation method thereof

Abstract

The present invention provides a kind of composition containing bird's nest acid, phospholipid and polyunsaturated fatty acid and preparation method thereof, composition, when not adding any additives, bird's nest acid is dispersed in DHA grease in functional ingredients, while solving the problem that DHA is easily oxidized, promotes brain development, regulates immunity, promotes the absorption and utilization of minerals in the intestine and the effects of beauty and skin care. Phospholipids can prevent the sedimentation of bird's nest acid in ω 3 polyunsaturated fatty acid grease, and are phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine. Not only can the sedimentation of bird's nest acid be prevented, but also the growth of nerve cells can be supported, thereby improving the absorption rate of DHA in the brain. Especially PS, itself can not only nourish the brain, enhance brain function, but also relieve mental stress and improve cognition, and is called "brain nutrient".

Description

[0001] The present invention is a divisional case of the invention patent application with patent application number 202110680816.3, entitled "An ω-3 polyunsaturated fatty acid composition and a preparation method thereof." Technical Field

[0002] The invention relates to an ω-3 polyunsaturated fatty acid composition and a preparation method thereof, belonging to the technical field of food health care. Background Art

[0003] As people's living standards improve, the public pays more and more attention to their health. Therefore, the acceptance of health products or nutritional supplements is also increasing. Health products, also known as functional foods, can regulate the body's functions and are suitable for consumption by specific groups of people. There are many types of health products, such as tea, wine, bee products, beverages, soups, fresh juices, medicinal foods, etc., which have requirements for color, fragrance, shape, and quality, and generally have no requirements on dosage. In recent years, health products for nutritional supplements for pregnant women and fetuses, brain development of infants and young children, and improving vision development have emerged in an endless stream, especially health products or supplements containing ω-3 polyunsaturated fatty acids (PUFAs).

[0004] Omega-3 polyunsaturated fatty acids (PUFAs) are long-chain fatty acids containing two or more carbon-carbon double bonds, with the first double bond at the methyl end occurring between the third and fourth carbon atoms. These include alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). DHA, in particular, plays a significant role in human health. Increasing DHA levels in food helps boost brain levels, thereby enhancing learning and memory, supporting healthy brain and nerve development, and preventing and treating vision loss and Alzheimer's disease. DHA is abundant in human brain cells, highly concentrated on the surface of neurons, comprising approximately 10% of brain cell fatty acids. It plays a crucial role in brain nerve conduction and synaptic growth and development, and its role in maintaining cell morphology and function cannot be ignored. DHA plays a crucial role in the formation of the fetal brain and cardiovascular system. Clinical evidence suggests that fetuses born to mothers with higher levels of DHA in their plasma have faster maturation of their central nervous systems. DHA is a long-chain, highly unsaturated fatty acid. Increased levels of DHA in biological membranes affect membrane fluidity, permeability, and receptor activity, thereby enhancing membrane function, strengthening the transmission of neural signals, and boosting brain and nervous system activity.

[0005] However, existing health products or supplements of this type on the market face stability issues, such as poor oxidative, physical, or sensory stability. To address this, various stabilizers are often added to the products. For example, Chinese patent CN106617074A adds antioxidant peptides isolated from whey protein to DHA microalgae oil to improve DHA stability. Other patents in various countries, such as EP2322169A1, EP3280395A1, and KR1020010017636A, all aim to improve DHA's antioxidant stability by adding antioxidants. This complicates the ingredients of these products and may affect their effectiveness.

[0006] Omega-3 polyunsaturated fatty acids are traditionally used to promote brain and vision development in infants, pregnant women, and their fetuses. Bird's nest acid is increasingly recognized for its effectiveness in promoting brain and vision development in infants, pregnant women, and their fetuses. However, bird's nest acid is poorly oil-soluble. Therefore, combining omega-3 polyunsaturated fatty acids and bird's nest acid to create a chemically and physically stable combination, and thus a product with stable properties and efficacy, is an urgent technical challenge.

[0007] In addition, other raw materials in products containing ω-3 polyunsaturated fatty acids and bird's nest acid need to be as small as possible to make production easier. On the other hand, they need to contribute to the stability of the external form of the composition and the health benefits of the product, which is a more difficult technical problem to solve. Summary of the Invention

[0008] In order to solve the above-mentioned defects and deficiencies in the prior art, the present invention provides an ω-3 polyunsaturated fatty acid composition and a preparation method thereof. The ω-3 polyunsaturated fatty acids, sialic acid and phospholipids in the composition work together to promote brain development and vision development in infants, pregnant women and fetuses in the body.

[0009] In order to solve the above technical problems, the present invention provides an ω-3 polyunsaturated fatty acid composition, comprising ω-3 polyunsaturated fatty acids, bird's nest acid and phospholipids.

[0010] The bird's nest acid is used to prevent or partially prevent the oxidation of ω-3 polyunsaturated fatty acids, and the phospholipid is used to uniformly disperse the bird's nest acid in the ω-3 polyunsaturated fatty acids, thereby improving the oxidative stability, physical stability and sensory stability of the composition; wherein the ω-3 polyunsaturated fatty acid is docosahexaenoic acid, or a combination of docosahexaenoic acid and eicosapentaenoic acid; the phospholipid is one or a combination of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine, preferably phosphatidylserine.

[0011] Bird's nest acid, also known as swiftlet's nest acid, is found most abundantly in the nervous system, primarily in brain gangliosides (65%) and glycoproteins (32%), with very little found in its free form (3%). The primary dietary source is breast milk. First, in promoting brain development: The human neurotransmission process is essentially a weak electrochemical reaction. When an electric current passes through it, bird's nest acid receives the electrical signal (due to its strong negative charge), causing calcium to be released from gangliosides. This calcium enters the presynaptic region through ion channels, opening the neuronal vesicles and releasing neurotransmitters. These neurotransmitters then cross the cell membrane and reach the postsynaptic region, allowing sodium to be transmitted. The entire neurotransmission process is essentially a transfer of charge, and bird's nest acid serves as the starting gun for this process, playing a crucial role. Second, in immune regulation: By binding to the cell surface, bird's nest acid enhances hydrophilicity, protects the cell surface, regulates immune cell activity, eliminates pathogens, and mediates molecular cross-linking on the cell surface. Bird's nest acid, modified on the surface of microbial pathogens, has a molecular mimicry effect, helping them successfully evade host immunity. Recent studies have shown that within vertebrates, bird's nest acid is recognized and bound by bird's nest lectins, acting as a ligand for endogenous receptors. It is also bound by pathogens and toxins, acting as a ligand for exogenous receptors. Third, in the intestinal tract: Bird's nest acid carries a strong negative charge and is typically located at the termini of glycoproteins or glycolipids on the cell membrane surface, providing the primary source of negative charge in the cell membrane. Due to the principle of opposites attracting, positively charged minerals such as calcium and some vitamins (e.g., vitamin B12) that enter the intestine readily bind to the strongly negatively charged bird's nest acid. Supplementation with bird's nest acid can enhance the body's absorption of nutrients. Fourth, in terms of whitening and anti-aging: Bird's nest acid can effectively inhibit the activity of tyrosine hydroxylase and dopa hydroxylase, preventing melanin production. Bird's nest acid also possesses antioxidant properties. Combining it with DHA can effectively enhance the antioxidant capacity of DHA, thereby extending the shelf life of DHA products.

[0012] Phosphatidylserine (PS) is a pale yellow powder at room temperature with a melting point of 135°C. Its molecular structure consists of three parts: a hydrophilic glycerol backbone as the head and two longer hydrocarbon chain lipophilic groups as the tail. The head is composed of three groups: a serine residue bound to a phosphate residue, linked to the C-3 hydroxyl group of glycerol; the other two hydroxyl groups of glycerol, esterified with fatty acids, form the tail. Its structure dictates its unique properties: amphiphilicity, meaning it possesses both hydrophilic and lipophilic properties. The negatively charged head is hydrophilic (or water-soluble), while the fatty acid tail is lipophilic (or fat-soluble). Omega-3 polyunsaturated fatty acids, such as DHA, are pale yellow to orange-yellow oily liquids. Therefore, due to its fat solubility, the lipophilic tail of PS dissolves in the DHA oil, leaving the hydrophilic head exposed, acting as a carrier for sialic acid and uniformly dispersed within the DHA oil, forming a suspension. At the same time, PS can combine with DHA through enzymatic action in the brain to form phospholipids in the cell membrane, supporting the growth of nerve cells.

[0013] This composition, without adding any auxiliary materials or adjuvants, can achieve good oxidative stability, physical stability, and sensory stability. As shown in Experimental Example 1, the composition exhibits oxidative stability: in an accelerated test at 60 degrees Celsius, the 72-hour oxidation inhibition rate is 10% or more, preferably 20% or more, and more preferably 50% or more; or / and, physical stability: the composition exhibits a sedimentation volume ratio of 50% or more, preferably 60% or more, and more preferably 80% or more within 6 months; or / and, sensory stability: the composition exhibits a sensory evaluation score of 8 or more, preferably 10 or more, and more preferably 12 or more after 6 months of storage.

[0014] Furthermore, the weight portion of bird's nest acid is 1-5 parts, the weight portion of ω-3 polyunsaturated fatty acids is 10-100 parts, and the weight portion of phospholipids is 10-150 parts; preferably, the weight portion of bird's nest acid is 2-4 parts, the weight portion of ω-3 polyunsaturated fatty acids is 20-80 parts, and the weight portion of phospholipids is 30-100 parts; more preferably, the weight portion of bird's nest acid is 3 parts, the weight portion of ω-3 polyunsaturated fatty acids is 60 parts, and the weight portion of phospholipids is 80 parts.

[0015] Furthermore, in the combination of docosahexaenoic acid and eicosapentaenoic acid, the weight percentage of docosahexaenoic acid (DHA) is at least 50%.

[0016] Furthermore, the composition also includes one or a combination of two or more of nervonic acid, pomegranate seed oil, sea buckthorn seed oil / sea buckthorn fruit oil, lutein, erythritol, and sorbitol.

[0017] Neuroacid, also known as squalane and cis-15-tetracosenoic acid, was first discovered in mammalian nerve tissue. It is a key component of neural membranes and a hallmark component of the medulla of cerebrosides. Scientists worldwide recognize it as the world's first and only miraculous substance capable of repairing and clearing damaged brain nerve pathways—nerve fibers—and promoting the regeneration of nerve cells. Neuroacid is a core natural component of brain nerve fibers and cells. A deficiency in neuratomic acid can lead to brain disorders such as stroke sequelae, Alzheimer's disease, cerebral palsy, cerebral atrophy, memory loss, insomnia, and forgetfulness. Neuroacid can fully cross the blood-brain barrier and directly act on nerve fibers to repair and clear them. It regenerates damaged and detached myelin sheaths, dissolves necrotic tissue that blocks pathways, and induces the growth and division of nerve fibers. This allows both information generated by nerve cells and external signals to be transmitted smoothly through the nerve fibers, ensuring unimpeded communication. This activates damaged, diseased, and dormant nerve cells, remodels neural networks, and restores partial or complete function in language, memory, sensation, and limb function, ultimately achieving complete recovery from brain diseases.

[0018] Seabuckthorn has been used in traditional Chinese medicine for thousands of years. The 8th-century Tibetan medical classic, "The Four Medical Classics," first recorded the use of seabuckthorn berries to treat gastrointestinal diseases and burns. The berries, leaves, rhizomes, and branches of seabuckthorn are rich in nutrients and medicinal properties, making them widely used as medicines and health supplements by residents of Europe and Central and South Asia. Seabuckthorn berry oil is rich in fatty acids, with unsaturated fatty acids comprising up to 86.3% of its oil composition, making it a high-quality source of unsaturated fatty acids. Saturated fatty acids in seabuckthorn berry oil include palmitoleic acid and stearic acid, while unsaturated fatty acids include linoleic acid (ω-6), oleic acid (ω-9), and eicosanoic acid (ω-9). Among these, palmitic acid (16:0) and palmitoleic acid (16:1) have the highest relative content.

[0019] In recent decades, the application of seabuckthorn in clinical medicine has gradually expanded. Numerous publications have documented the efficacy of seabuckthorn seed oil in improving the human immune system, preventing and treating cancer, enhancing the body's resistance to radiation, promoting tissue regeneration and accelerating ulcer healing, and treating respiratory, cardiovascular, and cerebrovascular diseases. Seabuckthorn seed oil contains up to 90% unsaturated fatty acids, primarily octadecenoic acid (ω-9) and octadecadienoic acid (ω-8), and contains a variety of bioactive substances, including unsaturated aldehydes.

[0020] Erythritol and sorbitol can improve the taste, are stable at high temperatures, are not easy to absorb moisture, have a mild cool feeling when chewing, have low sweetness, do not participate in sugar metabolism, have no effect on the blood sugar of pregnant women, and do not ferment in the colon, thus avoiding gastrointestinal discomfort; lutein can filter high-energy blue light, improve light adaptability, relieve visual fatigue, increase the pigment level in the macula, and reduce the risk of AMD.

[0021] Furthermore, the composition can be prepared into different dosage forms with or without adding auxiliary materials; preferably, the dosage forms include hard capsules; tablets including chewable tablets and lozenges; solid beverages including powders, granules, and mixed powders; candies including hard candies and soft candies; soft capsules; jellies; energy bars; chocolate or biscuits.

[0022] The present invention also provides a method for preparing an ω-3 polyunsaturated fatty acid composition, comprising dispersing guanidine in ω-3 polyunsaturated fatty acids, adding phospholipids, and stirring thoroughly to obtain a uniformly dispersed suspension preparation, and packaging the suspension preparation with or without adding excipients as a finished product; preferably, the composition has an oxidative stability of 10% or more, preferably 20% or more, and more preferably 50% or more, after an accelerated test at 60 degrees Celsius for 72 hours; or / and, physical stability of 50% or more, preferably 60% or more, and more preferably 80% or more, after a sedimentation volume ratio of 50% or more, and / or, sensory stability of 80% or more, preferably 10% or more, and more preferably 12% or more, after a sensory evaluation score of 12 months;

[0023] or

[0024] Add lecithin to ω-3 polyunsaturated fatty acids and mix evenly, then add swollen nest acid, and stir thoroughly to obtain a uniformly dispersed suspension preparation. The suspension preparation is packaged into a finished product with or without adding excipients. Preferably, the suspension has an oxidative stability: the composition is subjected to an accelerated test at 60 degrees, and the 72-hour oxidation inhibition rate is 10% or more, preferably 20% or more, and more preferably 50% or more; or / and, physical stability: the sedimentation volume ratio of the composition within 6 months is 50% or more, preferably 60% or more, and more preferably 80% or more; or / and, sensory stability: the sensory evaluation score of the composition after 6 months is 8 points or more, preferably 10 points or more, and more preferably 12 points or more;

[0025] or

[0026] The phospholipids and swollen acid are mixed and added to the ω-3 polyunsaturated fatty acids, and the mixture is stirred thoroughly to obtain a uniformly dispersed suspension preparation. The suspension preparation is packaged as a finished product with or without adding excipients; preferably, the suspension has an oxidative stability: the composition is subjected to an accelerated test at 60 degrees, and the 72-hour oxidation inhibition rate is above 10%, preferably above 20%, and more preferably above 50%; or / and, physical stability: the sedimentation volume ratio of the composition within 6 months is above 50%, preferably above 60%, and more preferably above 80%; or / and, sensory stability: the sensory evaluation score of the composition after 6 months is above 8 points, preferably above 10 points, and more preferably above 12 points.

[0027] Furthermore, the phospholipid is phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine; preferably, the phospholipid is phosphatidylserine.

[0028] The present invention also provides the use of the ω-3 polyunsaturated fatty acid composition in improving brain development, memory and thinking ability, vision, and reducing postpartum depression in infants and pregnant women.

[0029] The dosage of the ω-3 polyunsaturated fatty acid composition provided by the present invention is calculated based on the weight of the ω-3 polyunsaturated fatty acids, and the recommended dosage is at least 300 mg / day.

[0030] The beneficial technical effects achieved by the present invention: The present invention provides a composition for increasing ω-3 polyunsaturated fatty acids, wherein the functional ingredients include ω-3 polyunsaturated fatty acids, sialic acid and phospholipids. In the composition: 1. sialic acid can effectively improve the problem of DHA oxidation, and it itself also promotes brain development, regulates immunity, promotes the absorption and utilization of minerals in the intestine, and has the effects of beautifying the skin. 2. Since sialic acid is hydrophilic and insoluble in oils and fats, it is prone to precipitation in ω-3 polyunsaturated fatty acid oils and fats. Phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine, especially phosphatidylserine (PS): 2.1 can effectively prevent the precipitation of sialic acid in oils and fats, thereby improving the physical stability and sensory stability of the composition. 2.2 In addition, phosphatidylserine can also increase the amount of DHA that passes through the blood-brain barrier, thereby improving the bioavailability of DHA in the brain. 2.3PS can not only nourish the brain and enhance brain function, but also relieve mental stress and improve cognition, and is known as a "brain nutrient." DETAILED DESCRIPTION

[0031] The present invention will be further described below in conjunction with specific examples. The following examples are only used to more clearly illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention.

[0032] The present invention is further described below with reference to the embodiments.

[0033] Example 1

[0034] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein: the weight portion of bird's nest acid is 1 part, the weight portion of DHA is 10 parts, and the weight portion of phosphatidylcholine is 10 parts.

[0035] Example 2

[0036] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 2 parts, the weight portion of DHA is 20 parts, and the weight portion of phosphatidylcholine is 30 parts.

[0037] Example 3

[0038] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 3 parts, the weight portion of DHA is 40 parts, and the weight portion of phosphatidylcholine is 50 parts.

[0039] Example 4

[0040] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid, and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 3 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylcholine is 80 parts.

[0041] Example 5

[0042] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 4 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylcholine is 100 parts.

[0043] Example 6

[0044] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 5 parts, the weight portion of DHA is 80 parts, and the weight portion of phosphatidylcholine is 120 parts.

[0045] Example 7

[0046] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylcholine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 5 parts, the weight portion of DHA is 100 parts, and the weight portion of phosphatidylcholine is 150 parts.

[0047] Example 8

[0048] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylethanolamine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein: the weight portion of bird's nest acid is 1 part, the weight portion of DHA is 10 parts, and the weight portion of phosphatidylethanolamine is 10 parts.

[0049] Example 9

[0050] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylethanolamine for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 2 parts, the weight portion of DHA is 20 parts, and the weight portion of phosphatidylethanolamine is 30 parts.

[0051] Example 10

[0052] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylethanolamine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight parts of sialic acid are 3 parts, the weight parts of DHA are 40 parts, and the weight parts of phosphatidylethanolamine are 50 parts.

[0053] Example 11

[0054] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylethanolamine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight parts of sialic acid are 3 parts, the weight parts of DHA are 60 parts, and the weight parts of phosphatidylethanolamine are 80 parts.

[0055] Example 12

[0056] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylethanolamine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 4 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylethanolamine is 100 parts.

[0057] Example 13

[0058] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylethanolamine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 5 parts, the weight portion of DHA is 80 parts, and the weight portion of phosphatidylethanolamine is 120 parts.

[0059] Example 14

[0060] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylethanolamine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight parts of sialic acid are 5 parts, the weight parts of DHA are 100 parts, and the weight parts of phosphatidylethanolamine are 150 parts.

[0061] Example 15

[0062] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 1 part, the weight portion of DHA is 10 parts, and the weight portion of phosphatidylinositol is 10 parts.

[0063] Example 16

[0064] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 2 parts, the weight portion of DHA is 20 parts, and the weight portion of phosphatidylinositol is 30 parts.

[0065] Example 17

[0066] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 3 parts, the weight portion of DHA is 40 parts, and the weight portion of phosphatidylinositol is 50 parts.

[0067] Example 18

[0068] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 3 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylinositol is 80 parts.

[0069] Example 19

[0070] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 4 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylinositol is 100 parts.

[0071] Example 20

[0072] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 5 parts, the weight portion of DHA is 80 parts, and the weight portion of phosphatidylinositol is 120 parts.

[0073] Example 21

[0074] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, bird's nest acid and phosphatidylinositol for uniformly dispersing the bird's nest acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of bird's nest acid is 5 parts, the weight portion of DHA is 100 parts, and the weight portion of phosphatidylinositol is 150 parts.

[0075] Example 22

[0076] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 1 part, the weight portion of DHA is 10 parts, and the weight portion of phosphatidylserine is 10 parts.

[0077] Example 23

[0078] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 2 parts, the weight portion of DHA is 20 parts, and the weight portion of phosphatidylserine is 30 parts.

[0079] Example 24

[0080] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 3 parts, the weight portion of DHA is 40 parts, and the weight portion of phosphatidylserine is 50 parts.

[0081] Example 25

[0082] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 3 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylserine is 80 parts.

[0083] Example 26

[0084] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 4 parts, the weight portion of DHA is 60 parts, and the weight portion of phosphatidylserine is 100 parts.

[0085] Example 27

[0086] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 5 parts, the weight portion of DHA is 80 parts, and the weight portion of phosphatidylserine is 120 parts.

[0087] Example 28

[0088] The present invention provides an ω-3 polyunsaturated fatty acid composition, comprising DHA, sialic acid and phosphatidylserine for uniformly dispersing the sialic acid in ω-3 polyunsaturated fatty acid oil; wherein the weight portion of sialic acid is 5 parts, the weight portion of DHA is 100 parts, and the weight portion of phosphatidylserine is 150 parts.

[0089] The DHA used in the above embodiment can be selected from algae oil DHA, and the content of DHA in algae oil is about 35%.

[0090] Experimental Example 1: Evaluation of DHA Sample Stability

[0091] 1. The sedimentation stability of Examples 1-28 was evaluated using the sedimentation volume ratio index:

[0092] 100 ml of the product of Examples 1-28 was measured with a graduated cylinder, sealed, and the initial height H0 of the liquid was noted. The sample was placed in a constant temperature environment of 25 degrees Celsius, and the sedimentation was observed. The height H1 of the sedimentation surface was recorded, and then the sedimentation volume ratio F (F=H1 / H0) was calculated. The closer the F value is to 1, the more stable the suspension. Each example was repeated 3 times, and the results were averaged. The results are shown in Table 1.

[0093] Table 1 Statistics of sedimentation volume ratio (%) of Examples 1-28

[0094]

[0095]

[0096] As can be seen from Table 1, compared with the control group (3 parts of bird's nest acid + 60 parts of DHA), the solid sedimentation volume ratios of Examples 1-28 are all improved, indicating that after adding phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine, the physical stability of the composition is better, and the sedimentation rate of bird's nest acid is also significantly slower than that of the control group. In particular, phosphatidylserine performs better. After adding different concentrations of phosphatidylserine and placing for 30 days, the sedimentation volume ratios of bird's nest acid are all above 99%, among which Example 25 performs the best; according to the applicant's further long-term experimental results, Example 25 is made into a soft capsule, and the sedimentation volume ratio of bird's nest acid reaches more than 50% within two years.

[0097] 2. Composition for DHA oxidative stability analysis: including DHA 300mg, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine 400mg, and swiftlet acid 10mg. Group settings are as follows:

[0098] Experimental group 1: phosphatidylcholine + bird's nest acid + DHA

[0099] Experimental group 2: phosphatidylethanolamine + syringic acid + DHA

[0100] Experimental Group 3: Phosphatidylinositol + Bird's Nest Acid + DHA

[0101] Experimental Group 4: Phosphatidylserine + Bird's Nest Acid + DHA

[0102] Experimental Group 5: Bird's Nest Acid + DHA

[0103] Blank control group: DHA (limited manufacturers and indicators)

[0104] The DHA samples of the above groups were placed in a constant temperature oven at 60 degrees, and samples were taken every 12 hours. The peroxide value of the samples was detected using a fat oxidation stability analyzer using the titration method specified in GB5009.227-2016. Each sample was tested three times, and the results were averaged. The ability to inhibit the oxidation of DHA was expressed by the oxidation inhibition rate, and the calculation formula was: oxidation inhibition rate = (peroxide value of the blank control group - peroxide value of the experimental group) / peroxide value of the blank control group. The results are shown in Tables 2 and 3.

[0105] Table 2 Peroxide value (g / 100g) and inhibitor (%) of DHA samples after accelerated oxidation in different experimental groups

[0106]

[0107] The experimental results in Table 2 show that compared to the blank control group, experimental groups 1, 2, 3, 4, and 5 all significantly inhibited the growth of peroxide value, with experimental group 4 performing the best. Within 12 hours, the peroxide value inhibition rates of experimental groups 1-5 were all above 70% compared to the control group, and there was no significant difference in antioxidant capacity among the five experimental groups. By 60 hours, the peroxide value inhibition rate of experimental group 5 was significantly lower than that of experimental groups 1-4. This may be because, initially, sialic acid was evenly dispersed in the DHA oil, and its ability to inhibit the growth of peroxide value was no different from that of experimental groups 1-4. However, as the accelerated oxidation time increased, sialic acid began to settle and accumulate at the bottom of the DHA oil. The amount of sialic acid dispersed in the oil was limited, and therefore its ability to inhibit the growth of peroxide value began to weaken, showing no significant difference from the blank control group. This indirectly reflects that after adding phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine, bird's nest acid can be well dispersed in DHA oil. Comparing experimental groups 1 to 4, it can be found that experimental group 4 has a better ability to inhibit the increase of peroxide value.

[0108] Table 3 Peroxide value (g / 100g) and oxidation inhibition rate (%) of samples of Example 22 to Example 28 after accelerated oxidation for 72h

[0109]

[0110]

[0111] As can be seen from Table 3, in the 72h accelerated oxidation experiment, as the content of sialic acid increased, the peroxide value of DHA became lower and lower, and the oxidation inhibition rate became higher and higher, indicating that sialic acid can effectively improve the oxidation of DHA. Furthermore, the increase in the amount of phosphatidylserine can effectively alleviate the precipitation of sialic acid in DHA algae oil, so the peroxide value will also decrease accordingly.

[0112] 3. Sensory Stability Evaluation: 50 ml of sample from each experimental group was stored in a dry environment at room temperature for 24 months. Sensory evaluation was performed every three months and compared with the results at 0 months to determine sensory stability. Three parallel groups were set up for each group, and the evaluation scores were averaged. The results are shown in Table 5. The sensory evaluation criteria are shown in Table 4.

[0113] Table 4 Sensory stability standards

[0114]

[0115] Table 5 Sensory evaluation scores of each group

[0116]

[0117]

[0118] It can be seen from the sensory evaluation score statistics in Table 5 that compared with the sensory state at month 0, experimental groups 1 to 4 only underwent slight changes, with scores all above 8 points, and the overall sensory performance was stable. In particular, experimental group 4 scored 10.6 points in the 24-month sensory evaluation, which was only 27.4% higher than the score of 14.6 at month 0. This further verifies that the composition has good stability and a long shelf life. As can be seen from experimental group 5, bird's nest acid can prolong the oxidative stability period of DHA until the liquid precipitates and then delaminates, indicating that bird's nest acid has settled in DHA, and the composition has undergone significant changes in both color and tissue state. In experimental groups 1 to 4, due to the added phospholipids, especially experimental group 4, due to the addition of phosphatidylserine, bird's nest acid can be effectively prevented from settling, so it exhibits better stability in terms of sensory perception.

[0119] Example 29

[0120] The present invention provides a series of ω-3 polyunsaturated fatty acid compositions, each having the same formulation as in Examples 1 to 28, except that DHA is replaced by a mixture of DHA and EPA, wherein the weight percentage of DHA in the mixture is 50%.

[0121] Example 30

[0122] The present invention provides a series of ω-3 polyunsaturated fatty acid compositions, each having the same formulation as in Examples 1 to 28, except that DHA is replaced by a mixture of DHA and EPA, wherein the weight percentage of DHA in the mixture is 60%.

[0123] Example 31

[0124] The present invention provides a series of ω-3 polyunsaturated fatty acid compositions, the formulations of which are consistent with those of Examples 1 to 28, except that DHA is replaced by a mixture of DHA and EPA, wherein the weight percentage of DHA in the mixture is 80%.

[0125] Example 32

[0126] The present invention provides a series of ω-3 polyunsaturated fatty acid compositions, the formulations of which are consistent with those of Examples 1 to 28, except that DHA is replaced by a mixture of DHA and EPA, wherein the weight percentage of DHA in the mixture is 90%.

[0127] Example 33

[0128] The present invention provides a series of ω-3 polyunsaturated fatty acid compositions, the formulations of which are consistent with those of Examples 1 to 28, except that DHA is replaced by a mixture of DHA and EPA, wherein the weight percentage of DHA in the mixture is 99%.

[0129] Example 34

[0130] The present invention provides a series of ω-3 polyunsaturated fatty acid compositions, each having the same formulation as in Examples 1 to 28, except that DHA is replaced by a mixture of DHA and EPA, wherein the weight percentage of DHA in the mixture is 99.9%.

[0131] Example 35

[0132] The present invention provides two ω-3 polyunsaturated fatty acid compositions, wherein the dosage forms of the compositions are respectively chewable tablets and lozenges.

[0133] Example 36

[0134] The invention provides three ω-3 polyunsaturated fatty acid compositions, which are respectively in the form of powder, granules and mixed powder.

[0135] Example 37

[0136] The invention provides three ω-3 polyunsaturated fatty acid compositions, wherein the compositions are in the form of hard candy, center-filled candy and gel candy.

[0137] Example 38

[0138] The invention provides an ω-3 polyunsaturated fatty acid composition, which is in the form of a jelly.

[0139] Example 39

[0140] The invention provides an ω-3 polyunsaturated fatty acid composition, and the dosage form of the composition is an energy bar.

[0141] Example 40

[0142] The invention provides an ω-3 polyunsaturated fatty acid composition, and the dosage form of the composition is chocolate.

[0143] Example 41

[0144] The invention provides an ω-3 polyunsaturated fatty acid composition, which is in the form of biscuits.

[0145] Example 42

[0146] The invention provides an ω-3 polyunsaturated fatty acid composition. The composition is in the form of a soft capsule. The shell of the soft capsule is formed by pressing gelatin.

[0147] Example 43

[0148] The present invention provides a medicine for improving brain development, improving memory and thinking ability, improving vision and reducing postpartum depression in infants and pregnant women, comprising ω-3 polyunsaturated fatty acids, bird's nest acid and phosphatidylserine.

[0149] Example 44

[0150] The present invention provides a food for improving brain development, improving memory and thinking ability, improving eyesight and reducing postpartum depression in infants and pregnant women, comprising ω-3 polyunsaturated fatty acids, bird's nest acid and phosphatidylserine.

[0151] Example 45

[0152] The present invention provides a supplement for improving brain development, improving memory and thinking ability, improving vision and reducing postpartum depression in infants and pregnant women, comprising ω-3 polyunsaturated fatty acids, bird's nest acid and phosphatidylserine.

[0153] Example 46

[0154] The present invention provides a nutrient product for improving brain development, memory and thinking ability, vision and reducing postpartum depression in infants and pregnant women, comprising ω-3 polyunsaturated fatty acids, bird's nest acid and phosphatidylserine.

[0155] Example 47

[0156] The present invention provides a health care product for improving brain development, improving memory and thinking ability, improving eyesight and reducing postpartum depression in infants and pregnant women, comprising ω-3 polyunsaturated fatty acids, bird's nest acid and phosphatidylserine.

[0157] Example 48

[0158] The recommended dosage of an ω-3 polyunsaturated fatty acid composition is at least 300 mg / day based on the weight of the ω-3 polyunsaturated fatty acids.

[0159] Example 49

[0160] The present invention also provides a method for preparing an ω-3 polyunsaturated fatty acid composition, comprising dispersing swallic acid in ω-3 polyunsaturated fatty acids, adding phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine, and stirring thoroughly to obtain a uniformly dispersed suspension preparation, and packaging the suspension preparation with or without adding excipients to prepare a finished product.

[0161] Example 50

[0162] Phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine are added to ω-3 polyunsaturated fatty acids and mixed evenly, and then bird's nest acid is added and stirred thoroughly to obtain a uniformly dispersed suspension preparation. The suspension preparation is packaged as a finished product with or without adding excipients.

[0163] Example 51

[0164] Phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine and bird's nest acid are mixed and added into ω-3 polyunsaturated fatty acids, and stirred thoroughly to obtain a uniformly dispersed suspension preparation. The suspension preparation is packaged as a finished product with or without adding excipients.

[0165] Experimental Example 2 Animal Experiment

[0166] The present invention uses animal experiments to further illustrate that the composition can be better enriched in the brain than DHA alone, and can better improve the memory ability of experimental mice.

[0167] 1. Experimental animals: SPF-grade male mice, weighing 20±2g; SPF-grade male SD rats, weighing 199-232g.

[0168] 2. DHA enrichment test in the brain: 48 SPF mice were selected and divided into 6 groups. They were gavaged once daily, 2 mg each time. After 2 weeks of feeding, the fatty acids in the cerebral cortex of the mice were analyzed. The results are shown in Table 6. The content of the feeding ingredients in each group (the content of the ingredients is the same as in Experimental Example 1) is as follows:

[0169] Blank control group: soybean oil;

[0170] Experimental group 1: phosphatidylcholine + bird's nest acid + DHA

[0171] Experimental group 2: phosphatidylethanolamine + syringic acid + DHA

[0172] Experimental Group 3: Phosphatidylinositol + Bird's Nest Acid + DHA

[0173] Experimental Group 4: Phosphatidylserine + Bird's Nest Acid + DHA

[0174] Experimental Group 5: Bird's Nest Acid + DHA

[0175] Table 6 Statistics of DHA accumulation in mouse cerebral cortex (composition and content of fatty acids in mouse cerebral cortex, n=8, unit: %)

[0176]

[0177]

[0178] As shown in Table 6, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine can all contribute to the accumulation of DHA in the mouse brain. Based on the research on DHA in the application, it is speculated that phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine are all phospholipids that can bind to DHA, thereby helping DHA enter the brain tissue and accumulate there. For example, PS, phosphatidylserine, and DHA combine enzymatically in the brain to form the phospholipids of the cell membranes of neurons, thereby promoting the growth of neurons. The structure of PS reveals that the two long tails are two fatty acid chains linked to the end chains of phosphatidylserine. One can only be linked to saturated fatty acids, while the other can be linked to any fatty acid. DHA can be linked to this end group. The DHA carried on the tail by phosphatidylserine crosses the blood-brain barrier, promoting the regeneration of neurons, thereby increasing the accumulation of DHA in the brain.

[0179] 3. Verification of the effect on learning and memory ability of mice: If any two of the four tests, namely the platform jumping test, dark avoidance test, water maze test, and shuttle box test, show positive results, and the results of repeated tests are consistent, the group is judged to have the function of assisting in improving memory, and the test results are positive; among them:

[0180] 1) Platform Jumping Test: 60 mice were randomly divided into 6 groups of 10 mice each according to body weight. The mice were administered 2 mg of the drug once daily for 30 consecutive days. Training began 24 hours after the last administration. The animals were placed in a reaction chamber to acclimate for 3 minutes. Then, they were placed on a copper grid within the chamber and immediately electrified. The animals received an electric shock. Their normal reaction was to jump back onto the platform to avoid the noxious stimulus. Most animals might jump onto the grid again or multiple times, then quickly jump back onto the platform upon receiving the shock. This training process continued for 5 minutes. The number of errors during the 5-minute jump and the latency to the first jump were recorded as learning performance (memory retention). The test was repeated 24 hours later, and the latency and total number of errors within the 3-minute period for the shocked animals were recorded (memory retention). A memory extinction test was conducted again on the 5th day after training, and the latency and total number of errors within the 3-minute period for the shocked animals were recorded. The experimental results are shown in Tables 7-10.

[0181] Table 7 Body weight changes of mice during the platform test (x ± SD, g)

[0182]

[0183]

[0184] Table 8 Memory training results in the platform jumping test (x±SD)

[0185] Group Number of animals Incubation period (s) Number of errors (times) Error response rate Blank control group 10 27.1±5.5 10.3±2.9 10 / 10 Experimental Group 1 10 35.7±5.7 12.9±5.1 10 / 10 Experimental Group 2 10 28.5±10.5 11.1±3.2 10 / 10 Experimental Group 3 10 21.2±16.4 13.1±7.0 10 / 10 Experimental Group 4 10 44.2±15.2 11.3±8.0 10 / 10 Experimental Group 5 10 33.7±22.7 9.6±4.9 10 / 10

[0186] Table 9 Memory test results in the platform jumping test (x±SD)

[0187] Group Number of animals Incubation period (s) Number of errors (times) Error response rate Blank control group 10 65.8±24.9 9.0±5.7 10 / 10 Experimental Group 1 10 93.5±10.1 6.8±1.3 9 / 10 Experimental Group 2 10 92.7±26.1 5.7±1.5 7 / 10 Experimental Group 3 10 91.0±39.5 4.8±0.5 8 / 10 Experimental Group 4 10 94.4±32.8 5.3±1.2 6 / 10 Experimental Group 5 10 93.4±40.0 4.1±1.1 7 / 10

[0188] Table 10 Memory loss results in the platform jumping test (x±SD)

[0189] Group Number of animals Incubation period (s) Number of errors (times) Error response rate Blank control group 10 91.7±35.4 2.9±0.9 7 / 10 Experimental Group 1 10 110.9±43.2 1.9±0.7 7 / 10 Experimental Group 2 10 124.5±60.5 1.1±0.5 6 / 10 Experimental Group 3 10 116.4±41.8 1.4±1.3 6 / 10 Experimental Group 4 10 133.2±57.2 0.9±0.1* 5 / 10 Experimental Group 5 10 112.3±35.4 2.1±2.0 6 / 10

[0190] As shown in Tables 7-10, the performance of mice in the platform jumping test varied among the experimental groups. During memory training, the latency of each experimental group was prolonged relative to the blank control group, but the extent of the extension varied. The latency extension was most pronounced in experimental group 4. There were no significant differences between experimental groups 1, 2, and 3, but the latency was slightly improved compared to experimental group 5. In the memory test, all experimental groups showed prolonged latency, fewer errors, and a lower error response rate relative to the blank control group. The number of errors in experimental group 4 was significantly different (P < 0.05).

[0191] 2) Dark avoidance test: 60 mice were randomly divided into 6 groups of 10 mice each according to body weight. After 30 consecutive days of sample administration according to the dosage, training began the day after the last sample administration. During the test, the animal was placed in the light chamber with its face facing away from the hole. A timer was started. The animal passed through the hole into the dark chamber and received an electric shock. The timer automatically stopped, and the mouse was removed. The time required for each animal to enter the dark chamber from the light chamber to receive the electric shock was recorded. This is the incubation period. Training lasted 5 minutes, and the number of electric shocks within 5 minutes was recorded. The test was repeated 24 hours later, and an extinction test was performed 5 days later. The incubation period for each animal to enter the dark chamber, the total number of errors within 5 minutes, and the number of animals entering the dark chamber in each group were recorded. The experimental results are shown in Tables 11-14.

[0192] Table 11 Body weight changes of mice during the dark avoidance test (x ± SD, g)

[0193] Group Number of animals initial mid-term terminal stage weight gain Blank control group 10 20.3±0.9 34.5±3.9 39.2±5.7 18.9±5.9 Experimental Group 1 10 20.5±1.4 34.1±3.8 39.3±5.6 18.8±5.8 Experimental Group 2 10 20.1±0.4 33.9±1.9 41.2±2.4 21.1±4.8 Experimental Group 3 10 20.4±1.1 35.3±3.2 40.3±4.1 19.9±4.3 Experimental Group 4 10 20.3±1.9 36.3±5.7 42.0±6.8 21.7±6.6 Experimental Group 5 10 20.5±2.4 35.3±2.3 41.9±2.4 21.4±4.1

[0194] Table 12 Memory training results in the dark avoidance test (x±SD)

[0195] Group Number of animals Incubation period (s) Number of errors (times) Error response rate Blank control group 10 13.5±9.8 9.8±3.8 10 / 10 Experimental Group 1 10 14.0±1.1 10.4±2.6 10 / 10 Experimental Group 2 10 15.9±5.9 9.4±3.1 10 / 10 Experimental Group 3 10 24.7±11.6 9.0±3.6 10 / 10 Experimental Group 4 10 21.6±8.5 9.7±3.8 10 / 10 Experimental Group 5 10 18.4±5.7 9.6±4.9 10 / 10

[0196] Table 13 Memory test results in the dark avoidance test (x±SD)

[0197]

[0198]

[0199] Table 14 Memory extinction results in the dark avoidance test (x±SD)

[0200] Group Number of animals Incubation period (s) Number of errors (times) Error response rate Blank control group 10 51.7±28.6 7.1±2.6 10 / 10 Experimental Group 1 10 97.9±59.7 9.8±4.2 9 / 10 Experimental Group 2 10 135.8±49.1 8.2±5.1 7 / 10 Experimental Group 3 10 104.1±56.7 4.7±3.4 7 / 10 Experimental Group 4 10 138.0±61.0 3.3±2.6 6 / 10 Experimental Group 5 10 102.5±35.4 5.1±2.0 7 / 10

[0201] From the statistical results in Tables 11-14, we can see that in memory training, memory test and memory extinction, experimental groups 1-5 showed significant changes compared to the blank control group in memory training, memory test and memory extinction, and the latency time was prolonged to varying degrees. Among them, the number of errors in the memory extinction test of experimental group 4 showed a significant difference (P < 0.05).

[0202] Water maze test: 60 mice were randomly divided into 6 groups according to body weight, with 10 mice in each group. Samples were administered continuously for 30 days according to the dosage, and training began the day after the last sample administration. Once daily, the maze was run in a 15 cm deep, 24-26°C water temperature, and a 120 s time limit. Each entry into any blind end was counted as an error, and the time it took for the mice to reach the finish line and the number of errors were recorded. On the first day of training, a specific distance was selected for training. On the second day, the training distance was lengthened until 80% of the animals reached the finish line, and this training lasted for 3 days. On the fifth day, the entire distance was tested. After 5 days of training, an extinction test was performed. Finally, the number of errors, the time to reach the finish line, and the number of animals that reached the finish line within 120 s were calculated for each group of mice during training, testing, and extinction trials. The results are shown in Tables 15-17.

[0203] Table 15 Water maze test results of mice body weight changes during the test period (x ± SD, g)

[0204] Group Number of animals initial mid-term terminal stage weight gain Blank control group 10 21.3±0.8 35.2±4.3 40.9±5.5 19.6±5.3 Experimental Group 1 10 20.8±0.8 33.2±3.4 38.5±3.6 17.7±4.1 Experimental Group 2 10 19.8±0.2 32.9±1.5 40.7±2.4 20.9±0.7 Experimental Group 3 10 20.6±0.7 35.0±2.3 41.8±3.9 21.2±4.1 Experimental Group 4 10 20.1±1.7 35.2±5.2 41.5±6.8 21.4±6.4 Experimental Group 5 10 20.1±3.2 34.8±2.3 41.5±2.9 21.4±3.6

[0205] Table 16 Memory training and test results in water maze test (x±SD)

[0206]

[0207]

[0208] Table 17 Memory loss results in water maze test (x±SD)

[0209]

[0210] As can be seen from Tables 15-17, although the results of each experimental group have changed to varying degrees compared with the blank control group, there is no significant difference.

[0211] Shuttle box test: 60 rats were randomly divided into 6 groups based on body weight, with 10 rats in each group. Animals were dosed for 30 consecutive days. Training began the day after the last dose, with training sessions occurring every other day for 5 consecutive rounds. Rats were placed on either side of the box. After 20 seconds, a light and a beeping sound appeared for 20 seconds, followed by an electric shock within 10 seconds. Upon receiving the shock, the rats fled, a passive avoidance response. Conditioned stimuli were administered before each shock. After repeated reinforcement, rats, upon receiving the conditioned stimulus, jumped to the opposite side and blocked the photoelectric tube to avoid the shock, an active avoidance response. Training sessions were repeated every other day for 50 times, for 5 consecutive rounds. The number of responses, active avoidance duration, passive avoidance duration, and active avoidance rate were recorded. Memory loss was measured 6 and 26 days after training. Results are shown in Tables 18-20.

[0212] Table 18 Body weight changes of mice during the shuttle box test (x ± SD, g)

[0213] Group Number of animals initial mid-term terminal stage weight gain Blank control group 10 216.3±7.8 353.0±24.7 438.0±27.3 221.7±22.7 Experimental Group 1 10 216.3±7.3 352.5±26.5 462.0±50.7 245.7±45.0 Experimental Group 2 10 215.6±8.1 349.5±27.3 437.9±37.3 222.3±17.7 Experimental Group 3 10 217.2±7.4 349.1±20.3 445.8±36.6 228.6±32.1 Experimental Group 4 10 217.4±7.3 337.7±15.0 424.0±31.1 206.6±28.6 Experimental Group 5 10 215.9±3.2 346.2±6.1 430.5±5.3 214.6±48.3

[0214] Table 19 Memory training results in the shuttle box test (mean of 5 times, x ± SD)

[0215]

[0216]

[0217] Table 20 Memory extinction results in the shuttle box test (mean of 2 times, x ± SD)

[0218] Group Number of animals Active avoidance time (s) Passive avoidance time (s) Active avoidance rate (%) Blank control group 10 2.7±0.6 2.3±0.7 55.7 Experimental Group 1 10 2.4±0.8 2.7±0.1 56.3 Experimental Group 2 10 2.6±0.4 2.4±0.5 55.7 Experimental Group 3 10 2.9±0.7 2.3±0.9 53.0 Experimental Group 4 10 3.2±0.6 2.5±0.7 53.7 Experimental Group 5 10 2.6±0.5 2.4±0.1 59.4

[0219] As can be seen from Tables 18-20, in the shuttle box test, there were significant differences in various statistical indicators between the experimental groups and the blank control group, and no significant differences were found.

[0220] In summary, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylserine as phospholipids can not only disperse sialic acid evenly in DHA oil, but also help to enrich DHA in animal brain tissue, especially phosphatidylserine performs best.

[0221] The present invention has been disclosed above with preferred embodiments, which are not intended to limit the present invention. Any technical solutions obtained by adopting equivalent replacement or equivalent transformation solutions fall within the protection scope of the present invention.

Claims

1. An ω-3 polyunsaturated fatty acid composition for use in the preparation of a drug for promoting brain development, memory and thinking ability, vision, and reducing postpartum depression in infants and pregnant women, characterized by: The invention is composed of ω-3 polyunsaturated fatty acids, bird's nest acid and phospholipids, wherein the ω-3 polyunsaturated fatty acids are docosahexaenoic acid or a combination of docosahexaenoic acid and eicosapentaenoic acid; the phospholipids are one or a combination of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol and phosphatidylserine; the weight portion of bird's nest acid is 1-5 parts, the weight portion of ω-3 polyunsaturated fatty acids is 10-100 parts, and the weight portion of phospholipids is 10-150 parts.

2. The use according to claim 1, characterized in that: Oxidation stability of the composition: the composition is subjected to an accelerated test at 60 degrees, and the oxidation inhibition rate after 72 hours is above 10%.

3. The use according to claim 1, characterized in that: Physical stability: The sedimentation volume ratio of the composition within 6 months is greater than 50%.

4. The use according to claim 1, characterized in that: Sensory stability: The sensory evaluation score of the composition after being placed for 6 months is 8 points or more.

5. The use according to claim 1, characterized in that: The weight portion of bird's nest acid is 1-5 parts, the weight portion of ω-3 polyunsaturated fatty acid is 20-100 parts, and the weight portion of phospholipid is 10-100 parts.

6. The use according to claim 1, characterized in that: The weight portion of bird's nest acid is 2-4 parts, the weight portion of ω-3 polyunsaturated fatty acid is 20-80 parts, and the weight portion of phospholipid is 30-100 parts.

7. The use according to claim 1, characterized in that: The weight portion of swalnic acid is 3 parts, the weight portion of ω-3 polyunsaturated fatty acids is 60 parts, and the weight portion of phospholipids is 80 parts.

8. The use according to claim 1, characterized in that: In the combination of docosahexaenoic acid and eicosapentaenoic acid, the weight percentage content of docosahexaenoic acid is at least 50%.

9. The use according to claim 1, characterized in that: The composition can be prepared into different dosage forms with or without the addition of auxiliary materials.

10. The use according to claim 9, characterized in that: The dosage form is a soft capsule.

Images